Vaishali Sanchorawala MD
Professor, Hematology & Medical Oncology
Associate Director, Amyloidosis Center
72 E. Concord Street | (617) 358-4750vaishali.sanchorawala@bmc.org
vsanchor@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Biography
72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Other Positions
Education
MBBS, Seth G.S. Medical College
Publications
Muchtar E, Sanchorawala V, Hassan H, Hegenbart U, Schönland S, Lee HC, Qazilbash M, Kin A, Zonder J, Jacob E, Buadi F, Dispenzieri A, Dingli D, Arai S, Chin M, Chakraborty R, Lentzsch S, Magen H, Shkury E, Sarubbi C, Landau H, Gertz M. The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis. Am J Hematol. 2025 Apr 11. PMID: 40214172.
Published on 3/29/2025Prokaeva T, Jayaraman S, Klimtchuk E, Burke N, Spencer B, Nedelkov D, Chen H, Dasari S, McPhail ED, Pereira L, Payne MC, Wong S, Burks EJ, Sanchorawala V, Gursky O. An unusual phenotype of hereditary AApoAI amyloidosis caused by a novel Asp20Tyr substitution is linked to pH-dependent aggregation of apolipoprotein A-I. Biochim Biophys Acta Mol Basis Dis. 2025 Jun; 1871(5):167820. PMID: 40164396.
Published on 3/25/2025Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Singh Bawa P, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. Amyloid. 2025 Jun; 32(2):179-192. PMID: 40134188.
Published on 3/20/2025Battaglini J, Henderson J, Sanchorawala V, Szalat R. Teclistamab therapy for refractory type 1 cryoglobulinemia. Haematologica. 2025 Mar 20. PMID: 40109179.
Published on 3/3/2025Dodge MC, Prokaeva T, Mendelson L, Joshi T, Sanchorawala V, Kataria Y. High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis. J Appl Lab Med. 2025 Mar 03; 10(2):315-324. PMID: 39495058.
Published on 2/24/2025Muchtar E, Dispenzieri A, Sanchorawala V, Hassan H, Mwangi R, Maurer M, Buadi F, Lee HC, Qazilbash M, Kin A, Zonder J, Arai S, Chin MM, Chakraborty R, Lentzsch S, Magen H, Shkury E, Sarubbi C, Landau H, Schönland S, Hegenbart U, Gertz M. A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis. Bone Marrow Transplant. 2025 May; 60(5):595-602. PMID: 39994333.
Published on 2/21/2025Muchtar E, Grogan M, Aus dem Siepen F, Waddington-Cruz M, Misumi Y, Carroll AS, Clarke JO, Sanchorawala V, Milani P, Caccialanza R, Da Prat V, Pruthi R, Quintana LF, Bridoux F. Supportive care for systemic amyloidosis: International Society of Amyloidosis (ISA) expert panel guidelines. Amyloid. 2025 Jun; 32(2):93-116. PMID: 39985185.
Published on 2/21/2025Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri A, Dunnmon P, Emdin M, Abou Ezzeddine OF, Falk RH, Fontana M, Grodin JL, Guthrie S, Jerosch-Herold M, Hofling AA, Hsu K, Lin G, Masri A, Maurer MS, Mittmann C, Prasad K, Quarta CC, Race JM, Rajendran JG, Ruberg FL, Sachdev V, Sanchorawala V, Signorovitch J, Sirac C, Soman P, Sorensen J, Sperry BW, Stephens AW, Stockbridge NL, Vest J, Wall JS, Wechalekar A, Welsh C, Lousada I. Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. JACC Cardiovasc Imaging. 2025 May; 18(5):602-617. PMID: 39985507.
Published on 1/31/2025Staron A, Sanchorawala V. Current landscape of clinical management for systemic light chain amyloidosis. Future Cardiol. 2025 Mar; 21(4):203-205. PMID: 39885778.
Published on 1/14/2025Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581. PMID: 39624016.
Media Mentions
Published on 10/13/2024
New study underway in Boston for people with advanced stage of AL amyloidosis
Published on 6/27/2024
: Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/27/2024
Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/26/2024
Published on 6/26/2024
Published on 9/22/2022
There’s New Proof Crispr Can Edit Genes Inside Human Bodies
Published on 8/5/2022
Young Black Patients With AML Face Significantly Worse Outcomes
Published on 7/20/2022
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Published on 7/14/2022
Published on 7/14/2022
View full list of 15 media mentions.